Clinical Trials Directory

Trials / Completed

CompletedNCT05810558

Impact of Glycine Therapy on Peri-implant Mucositis

Impact of Glycine-augmented Prophylaxis on Resolution of Peri-implant Mucositis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Ohio State University · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

The purpose of this research study is to determine the impact of glycine powder air-abrasive debridement (GPAD) on the microbiology of the tissues surrounding dental implants with health and inflammation (peri-implant mucositis).

Detailed description

Peri-implant mucositis, or the infection of the gingival tissues surrounding a dental implant, and peri-implantitis, or the infection of the gingival tissue surrounding a dental implant with bone loss, can lead to the failure and eventual loss of dental implants. The prevalence of peri-implant mucositis ranges from 30.7-43% and the prevalence of peri-implantitis ranges from 9.6-22% with non-smokers. Traditional treatment of this disease has been through biofilm removal using ultrasonic instrumentation. Glycine is a non-essential amino acid that possesses an anti-inflammatory, immunomodulary, and a cytoprotective effect. The goal of this investigation is to examine the impact of glycine-augmented biofilm removal on resolution of peri-implant mucositis

Conditions

Interventions

TypeNameDescription
PROCEDUREglycine powder air-powered debridementThe intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
PROCEDUREUltrasonic instrumentationThe control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste

Timeline

Start date
2016-06-16
Primary completion
2017-09-30
Completion
2020-12-30
First posted
2023-04-12
Last updated
2023-04-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05810558. Inclusion in this directory is not an endorsement.